» Articles » PMID: 20042686

Follicle-stimulating Hormone, Interleukin-1, and Bone Density in Adult Women

Overview
Specialty Physiology
Date 2010 Jan 1
PMID 20042686
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have indicated that follicle-stimulating hormone (FSH) promotes bone loss. The present study tested the hypothesis that FSH enhances the activity of bone-resorbing cytokines [interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6], either by inducing their secretion or by altering their receptor expression. Thirty-six women between the ages of 20 and 50 were assessed for bone mineral density (BMD), reproductive hormone, cytokine ligand and soluble receptor concentrations, and surface expression of cytokine receptors on monocytes. In addition, isolated mononuclear cells were incubated in vitro with exogenous FSH. Univariate regression analyses indicated that BMD was inversely related to serum FSH (r = -0.29 to -0.51, P = 0.03-0.001, depending upon the skeletal site). Physical activity and body composition were also identified as significant factors by multiple regressions. Exogenous FSH induced isolated cells to secrete IL-1beta, TNF-alpha, and IL-6 in proportion to the surface expression of FSH receptors on the monocytes. Endogenous (serum) FSH concentrations correlated with the circulating concentrations of these cytokines. None of these individual cytokines was related to BMD, but the IL-1beta to IL-1 receptor antagonist (IL-1Ra) ratio was inversely related to BMD (r = -0.53, P = 0.002) in all but the most physically active women, who had significantly lower expression of IL-1 type I receptors relative to type II (decoy receptors, P = 0.01). Physical activity also correlated positively with secretion of inhibitory soluble IL-1 receptors (r = 0.53, P = 0.003). Moreover, IL-1Ra correlated strongly with percent body fat (r = 0.66, P < 0.0001). These results indicate that BMD is related to FSH concentration, physical activity, and body composition. Although each of these factors likely has direct effects on bone, the present study suggests that each may also influence BMD by modulating the activity of the osteoresorptive cytokine IL-1beta.

Citing Articles

Neuroendocrinology of bone.

Kim S, Sultana F, Korkmaz F, Rojekar S, Pallapati A, Ryu V Pituitary. 2024; 27(6):761-777.

PMID: 39096452 DOI: 10.1007/s11102-024-01437-5.


To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques.

Fan W, Meng Y, Zhang J, Li M, Zhang Y, Qu X Sci Rep. 2023; 13(1):19016.

PMID: 37923747 PMC: 10624676. DOI: 10.1038/s41598-023-45699-8.


Pituitary crosstalk with bone, adipose tissue and brain.

Zaidi M, Yuen T, Kim S Nat Rev Endocrinol. 2023; 19(12):708-721.

PMID: 37715028 PMC: 11730177. DOI: 10.1038/s41574-023-00894-5.


Extra-Gonadal and Non-Canonical Effects of FSH in Males.

Spaziani M, Carlomagno F, Tenuta M, Sesti F, Angelini F, Bonaventura I Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375761 PMC: 10300833. DOI: 10.3390/ph16060813.


Association of follicle-stimulating hormone with bone turnover markers and bone mineral density in Chinese women across the menopausal transition.

Li L, Pi Y, Zhang H, Dai R, Yuan L, Sheng Z J Clin Lab Anal. 2023; 37(9-10):e24899.

PMID: 37272770 PMC: 10388221. DOI: 10.1002/jcla.24899.


References
1.
Abrahamsen B, Bonnevie-Nielsen V, Ebbesen E, Gram J, Beck-Nielsen H . Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2000; 15(8):1545-54. DOI: 10.1359/jbmr.2000.15.8.1545. View

2.
Recker R, Lappe J, Davies K, Heaney R . Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res. 2000; 15(10):1965-73. DOI: 10.1359/jbmr.2000.15.10.1965. View

3.
Santoro N, Brown J, Adel T, Skurnick J . Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996; 81(4):1495-501. DOI: 10.1210/jcem.81.4.8636357. View

4.
Holloway W, Collier F, Aitken C, Myers D, Hodge J, Malakellis M . Leptin inhibits osteoclast generation. J Bone Miner Res. 2002; 17(2):200-9. DOI: 10.1359/jbmr.2002.17.2.200. View

5.
Slemenda C, Hui S, Longcope C, JOHNSTON C . Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest. 1987; 80(5):1261-9. PMC: 442379. DOI: 10.1172/JCI113201. View